Evidence map›Paper›PMID 38884787›Full record

ArticleAnnals of hematology2024

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

E U Suárez, B Boluda, E Lavilla, M Tormo, C Botella, C Gil, S Vives, C Rodríguez, J Serrano, M J Sayas and 26 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

E U SuárezHospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
B BoludaHospital Universitari I Politécnic-IIS La Fe, Valencia, Spain.
E LavillaHospital Universitario Lucus Augusti, Lugo, Spain.
M TormoHospital Clínico Universitario de Valencia, Valencia, Spain.
C BotellaHospital General Universitario de Alicante, Alicante, Spain.
C GilHospital General Universitario de Alicante, Alicante, Spain.
S VivesICO-Hospital Germans Trias I Pujol, Badalona, Spain.
C RodríguezHospital Universitario Dr Negrín, Las Palmas, Spain.
J SerranoHospital Universitario Reina Sofía, Córdoba, Spain.
M J SayasHospital Universitario Dr. Peset, Valencia, Spain.
P Martínez-SánchezHospital Universitario 12 de Octubre, Madrid, Spain.
F RamosHospital Universitario de León, León, Spain.
T BernalHospital Universitario Central de Asturias, Oviedo, Spain.
L AlgarraHospital Universitario General de Albacete, Albacete, Spain.
J M Bergua-BurguesHospital San Pedro de Alcántara, Cáceres, Spain.
J A Pérez-SimónHospital Universitario Virgen del Rocío, Seville, Spain.
P HerreraHospital Universitario Puerta de Hierro, Majadahonda, Spain.
M BarriosHospital Regional Universitario de Málaga, Málaga, Spain.
V Noriega-ConcepciónHospital Universitario de A Coruña, A Coruña, Spain.
J A Raposo-PugliaHospital Universitario Puerta del Mar de Cádiz, Cádiz, Spain.
R AyalaHaematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, CNIO, CIBERONC, Madrid, Spain.
E BarragánHospital Universitari I Politécnic-IIS La Fe, Valencia, Spain.
D Martínez-CuadrónHospital Universitari I Politécnic-IIS La Fe, Valencia, Spain.
M L AmigoHospital General Universitario Morales Meseguer, Murcia, Spain.
J L López-LorenzoHospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
A Lázaro-GarcíaHospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
J E GuimaraesCentro Hospitalar São João, Oporto, Portugal.
M ColoradoHospital Universitario Marqués de Valdecilla, Santander, Spain.
R García-BoyeroHospital General Universitario de Castellón, Castellón de La Plana, Spain.
B De Rueda-CillerHospital Universitario Miguel Servet, Saragossa, Spain.
M Foncillas-GarcíaHospital Universitario Infanta Leonor, Madrid, Spain.
A HongHospital Universitario Doctor José Molina Orosa, Arrecife, Spain.
J LabradorHospital Universitario de Burgos, Burgos, Spain.
J M Alonso-Dominguez *Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain. juan.adominguez@fjd.es.
P Montesinos *Hospital Universitari I Politécnic-IIS La Fe, Valencia, Spain.
PETHEMA group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FLT3-ITD and NPM1 mutations are key to defining the genetic risk profile of acute myeloid leukemia (AML). We aimed to assess the prognostic features of the FLT3-ITD and NPM1 mutations in old and/or unfit individuals with AML treated with non-intensive therapies in the era before azacitidine-venetoclax approbation. The results of various non-intensive regimens were also compared. We conducted a retrospective analysis that included patients treated with different non-intensive regimens, between 2007 and 2020 from PETHEMA AML registry. We compiled 707 patients with a median age of 74 years and median follow-up time of 37.7 months. FLT3-ITD patients (N = 98) showed a non-significant difference in overall survival (OS) compared to FLT3-ITD negative-patients (N = 608) (P = 0.17, median OS was 5 vs 7.3 months respectively). NPM1-mutated patients (N = 144) also showed a non-significant difference with NPM1 wild type (N = 519) patients (P = 0.25, median OS 7.2 vs 6.8 respectively). In the Cox regression analysis neither NPM1 nor FLT3-ITD nor age were significant prognostic variables for OS prediction. Abnormal karyotype and a high leukocyte count showed a statistically significant deleterious effect. Azacitidine also showed better survival compared to FLUGA (low dose cytarabine plus fludarabine). NPM1 and FLT3-ITD seem to lack prognostic value in older/unfit AML patients treated with non-intensive regimens other than azacitidine-venetoclax combination.

Indexed as

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationNuclear ProteinsNucleophosminAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMalePrognosisRetrospective StudiesSurvival RateVidarabineFLT3 protein, humanfludarabinefms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminVidarabineAcute myeloid leukemiaElderlyFms-like tyrosine kinase 3 (FLT3) mutationHypomethylatingNucleophosmin 1 (NPM1) mutationPETHEMATreatment

Identifiers

PMID38884787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.